What is the difference between ARA-290 and Humanin?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Humanin: Mitochondria-derived peptide; binds gp130 receptor, activates STAT3/JAK pathway; inhibits BAX-mediated apoptosis; improves insulin sensitivity

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Humanin FDA approved?

Humanin is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Humanin administered in research settings?

In research settings, Humanin is typically administered via the subcutaneous or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Humanin

Peptide Comparison

ARA-290 vs Humanin

Name: ARA-290 vs Humanin — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →

Humanin

LongevityNot EvaluatedResearch Only

Half-life: ~2-4 hours

10 providers listed

Full Humanin profile →

Bottom line

ARA-290 carries stronger published evidence (RCT, 2 key studies) than Humanin (Animal, 5); both are research compounds.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

Humanin

Half-life

~2-4 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
Less frequent dosing (longer half-life)	Humanin
Lower typical price per mg	ARA-290
More provider options (17 vs 10)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Humanin

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

~2-4 hours

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

subcutaneous, intranasal

Availability

Research Only

Providers

17 listed

10 listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

Mitochondria-derived 21-aa cytoprotective peptide encoded in 12S rRNA. No FDA approval, no NDA or IND. Research interest in aging and neuroprotection. Research use only.

Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

Humanin

Animal · 5 key studies · most recent 2026

Research Citations

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

Humanin

Animal2026 · Biomedicines

Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.

Animal2026 · Toxicol Ind Health

Humanin improved the rotenone-induced reactive oxygen species formation in PC12 cells by modulating the SIRT3…

Animal2026 · Metabolites

Humanin Restores Metabolic Hormone Homeostasis of Leptin, Ghrelin, Irisin and Asprosin in Streptozotocin-Indu…

Animal2026 · Res Sq

Neuroprotective Effect of Intraperitoneal Humanin-G in Retinal Degeneration of Royal College of Surgeons Rats.

+1 more

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Humanin

Mitochondria-derived peptide; binds gp130 receptor, activates STAT3/JAK pathway; inhibits BAX-mediated apoptosis; improves insulin sensitivity

Research Areas

neuroprotectionanti-apoptoticmetabolic improvementcardiovascular protection

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Humanin

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ARA-290

$4.95/mg

$3.91 – $5.56 range

34 vendors

View price index →Find providers →

Humanin

$11.84/mg

$6.83 – $14.60 range

8 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ARA-290

17 listed

Browse directory →

Providers offering

Humanin

10 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Humanin — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ara-290/humanin

https://peptidebase.io/peptides/compare/ara-290/humanin Methodology License Download JSON Download CSV